Epidermal Growth Factor Receptor Emerges as a Viable Target for Reducing Tumorigenicity of MDCK Cells

Di Yang1,2,3,4, Yuejiao Liao1,2,3, Lingwei Huang2,5

  • 1College of Veterinary Medicine, Gansu Agricultural University, Lanzhou 730070, China.

Genes
|September 28, 2024
PubMed

Insights

Epidermal growth factor receptor (EGFR) drives tumorigenicity in MDCK cells used for influenza vaccines. Reducing EGFR inhibits tumor growth and increases vaccine yield, offering a safer alternative to traditional methods.

Area of Science:

  • Biotechnology
  • Cell Biology
  • Virology

Background:

  • MDCK cells are preferred for influenza vaccine production over hen eggs.
  • Tumorigenicity of MDCK cells is a significant safety concern.
  • Epidermal growth factor receptor (EGFR) is implicated in MDCK cell tumorigenicity.

Purpose of the Study:

  • To investigate the role of EGFR in MDCK cell tumorigenicity and influenza virus susceptibility.
  • To identify EGFR-interacting proteins and signaling pathways involved in tumorigenesis.
  • To evaluate EGFR modulation as a strategy for improving vaccine production safety and efficiency.

Main Methods:

  • Established EGFR-knockdown and EGFR-overexpression MDCK cell lines.
  • Performed in vitro assays for cell growth, migration, and clonogenic ability.
  • Conducted in vivo tumorigenicity studies in nude mice.
  • Utilized GST pull-down, mass spectrometry, and bioinformatics to identify interacting proteins.
  • Confirmed protein and gene expression of signaling pathway molecules.

Main Results:

  • EGFR overexpression enhanced MDCK cell proliferation, migration, and clonal formation.
  • EGFR knockdown significantly reduced tumorigenesis and increased influenza virus titers.
  • Identified 21 EGFR-interacting proteins, confirming AKT1, CDK4, GNB2, and MAPK8.
  • EGFR activates the PI3K-AKT signaling pathway, promoting cell proliferation and tumorigenesis.

Conclusions:

  • EGFR plays a critical role in MDCK cell tumorigenesis and influences influenza virus susceptibility.
  • Targeting EGFR can mitigate tumorigenicity and enhance influenza vaccine production.
  • EGFR interacts with GNB2, activating the PI3K-AKT pathway, controlling cell cycle, and promoting proliferation.